Patents/Assignees

Blueprint Medicines Corporation

19 patents in portfolio

US12595265utility2026
Inhibitors of Activin Receptor-like Kinase
0 cites
US12583856utility2026
Inhibitors of Protein Kinase A
0 cites
US12552795utility2026
Pyrrolotriazine Derivatives for Treating Kit-and Pdgfra-mediated Diseases
0 cites
US12545684utility2026
CDK2 Inhibitors
0 cites
US12448379utility2025
Wild Type Kit Inhibitors
0 cites
US12269824utility2025
Wild Type Kit Inhibitors
0 cites
US12252494utility2025
Dosing Regimens of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for Treatment of Indolent Systemic Mastocytosis
0 cites
US12202844utility2025
MAP4K1 Inhibitors
0 cites
US12172983utility2024
EGFR Inhibitors
0 cites
US12060354utility2024
Crystalline Forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and Methods of Making
0 cites
US12042495utility2024
MAP4K1 Inhibitors
0 cites
US11999744utility2024
Crystalline Forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and Methods of Making
0 cites
US11970498utility2024
CDK2 Inhibitors
0 cites
US11964980utility2024
Crystalline Forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1- F][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and Methods of Making
0 cites
US11932648utility2024
CDK2 Inhibitors
0 cites
US11872192utility2024
RET Inhibitor for Use in Treating Cancer Having a RET Alteration
0 cites
US11827642utility2023
Compositions Useful for Treating Disorders Related to KIT
0 cites
US11718602utility2023
EGFR Inhibitors
0 cites
US11634422utility2023
Inhibitors of Activin Receptor-like Kinase
0 cites